Cellectis (CLLS) and Its Peers Head to Head Review

Cellectis (NASDAQ:CLLS) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Cellectis to similar companies based on the strength of its earnings, analyst recommendations, profitability, institutional ownership, valuation, dividends and risk.

Earnings and Valuation

This table compares Cellectis and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cellectis	$79.59 million	-$67.59 million	-1.65
Cellectis Competitors	$691.14 million	$10.43 million	-15.00

Cellectis’ competitors have higher revenue and earnings than Cellectis. Cellectis is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

63.9% of Cellectis shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Cellectis and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Cellectis Competitors	-9,046.59%	-199.78%	-30.61%

Analyst Recommendations

This is a summary of current recommendations for Cellectis and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	2	2	2	1	2.29
Cellectis Competitors	9828	15118	45430	1585	2.54

Cellectis presently has a consensus target price of $5.46, suggesting a potential upside of 410.28%. As a group, “Biotechnology” companies have a potential upside of 102.60%. Given Cellectis’ higher possible upside, research analysts clearly believe Cellectis is more favorable than its competitors.

Volatility and Risk

Cellectis has a beta of 3.21, indicating that its share price is 221% more volatile than the S&P 500. Comparatively, Cellectis’ competitors have a beta of 1.14, indicating that their average share price is 14% more volatile than the S&P 500.

Summary

Cellectis beats its competitors on 9 of the 13 factors compared.

Cellectis Company Profile

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.